Editas Medicine, Inc. EDIT
2.55 USD -0.17 (-6.25%)
At closeNov 5, 2026, 7:46 PM EST
2.53 -0.02 -0.78%
After hours · Nov 5, 7:46 PM ET
2.42 Day range 2.68
1.66 52-week range 3.75
- YTD
- +24.39%
- 1 year
- -8.27%
News
defenseworld.net Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average – Here’s Why Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $2.83 and traded as low as…
globenewswire.com Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today…
zacks.com EDIT Set to Begin First-in-Human Study in Hypercholesterolemia Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
benzinga.com Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6 Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overweight and raises the price target from $4 to $6.
benzinga.com Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) and has also…
globenewswire.com Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety…
defenseworld.net Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50-Day Moving Average – Here’s Why Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $2.85 and traded as low as…
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
benzinga.com This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.
benzinga.com Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
benzinga.com Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
defenseworld.net Bank of New York Mellon Corp Invests $851,000 in Editas Medicine, Inc. $EDIT Bank of New York Mellon Corp purchased a new position in shares of Editas Medicine, Inc. (NASDAQ: EDIT) during the second quarter, according to its most recent 13F filing with the SEC. The…
marketbeat.com Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for…
globenewswire.com Editas Medicine Reports Inducement Grants to New Chief Medical Officer CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced…
marketbeat.com Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial…
globenewswire.com Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
defenseworld.net BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT BlackRock Inc. acquired a new stake in Editas Medicine, Inc. (NASDAQ: EDIT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The…
globenewswire.com Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today…
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
zacks.com Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
benzinga.com Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of…
globenewswire.com Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,…
globenewswire.com Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D. Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401…
benzinga.com Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in…
forbes.com The Healthcare M&A Wave In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
fool.com CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
globenewswire.com Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today…
benzinga.com Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.- benzinga.com Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of…
globenewswire.com Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Editas Medicine Launches Public Stock Offering to Raise Capital Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering…
globenewswire.com Editas Medicine Announces Proposed Public Offering CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced…- benzinga.com Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in…
- benzinga.com Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For Hyperlipidemia The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston, including one oral presentation and two poster presentations, as…
- benzinga.com Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4 Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3.5 to $4.
- benzinga.com Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of…
- benzinga.com Editas Medicine To Present New Preclinical Data Demonstrating Progress Of EDIT-401 As Potential Treatment For Hyperlipidemia At Multiple Upcoming Conferences Five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral…
benzinga.com Editas Medicine Says USPTO Upholds PTAB Ruling Favoring Broad Institute In CRISPR Patent Interference Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office…- benzinga.com Editas Medicine Sees USPTO Reaffirm Broad Institute's CRISPR Patent Priority Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office…
- benzinga.com Jones Trading Upgrades Editas Medicine to Buy, Announces $8 Price Target Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and announces $8 price target.
benzinga.com Editas Medicine Q4 Earnings Assessment - benzinga.com Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of…
- benzinga.com Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of…
- benzinga.com Editas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At American Heart Association Scientific Sessions Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at…
benzinga.com Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.- benzinga.com Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy Congress, October 7–10, 2025, In Seville, Spain Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming…
benzinga.com My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
benzinga.com Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - benzinga.com HC Wainwright & Co. Reiterates Buy on Editas Medicine, Maintains $5 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with a Buy and maintains $5 price target.